Revisiting an old friend: Manganese-based MRI contrast agents

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 3, Issue 2, 2011, Pages 162-173

  Pan, Dipanjan ^a   Caruthers, Shelton D ^a   Senpan, Angana ^a   Schmieder, Ann H ^a   Wickline, Samuel A ^a   Lanza, Gregory M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD POOL; CONTRAST AGENT; CONTRAST ENHANCEMENT; CONTRAST MATERIAL; HIGH SPATIAL RESOLUTION; KIDNEY DISEASE; MOLECULAR IMAGING; MOLECULAR LEVELS; MRI CONTRAST AGENTS; NANO PARTICULATES; NEPHROGENIC SYSTEMIC FIBROSIS; NON-INVASIVE; PARAMAGNETIC CONTRASTS; SMALL MOLECULES; SUPERPARAMAGNETICS;

DISEASE CONTROL; GADOLINIUM; LAKES; MANGANESE; PARAMAGNETIC MATERIALS; RESONANCE; SUPERPARAMAGNETISM;

MAGNETIC RESONANCE IMAGING;

IRON OXIDE; LIPOSOME; MANGANESE; POLYCARBOXYLATE CEMENT; PORPHYRIN; CONTRAST MEDIUM; NANOPARTICLE;

CHEMICAL STRUCTURE; CONTRAST ENHANCEMENT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LD 50; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; ANIMAL; DIAGNOSTIC USE; PROCEDURES;

ANIMALS; CONTRAST MEDIA; HUMANS; MAGNETIC RESONANCE IMAGING; MANGANESE; NANOPARTICLES;

EID: 79551698042     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.116     Document Type: Review

References (59)

1. Pan D, Lanza GM, Wickline SA, Caruthers SD. Nanomedicine: perspective and promises with ligand-directed molecular imaging. Eur J Radiol 2009, 70:274-285.
2. Pan D, Caruthers SD, Chen J, Winter PM, Senpan A, Schmieder AH, Wickline SA, Lanza GM. Nanomedicine strategies for molecular targets with MRI and optical imaging. Future Med Chem 2010, 2:471-491.
3. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003, 17:545-580.
4. Chan KW, Wong W-T. Small molecular gadolinium(III) complexes as MRI contrast agents for diagnostic imaging. Coord Chem Rev 2007, 17:2428-2451.
5. Sieber MA, Steger-Hartmann T, Lengsfeld P, Pietsch H. Gadolinium-based contrast agents and NSF: evidence from animal experience. J Magn Reson Imaging 2009, 30:1268-1276.
6. Prince MR, Zhang HL, Prowda JC, Grossman ME, Silvers DN. Nephrogenic systemic fibrosis and its impact on abdominal imaging. Radiographics 2009, 29:1565-1574.
7. Idée JM, Port M, Dencausse A, Lancelot E, Corot C. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am 2009, 47:855-869.
8. Thomsen HS. Nephrogenic systemic fibrosis: history and epidemiology. Radiol Clin North Am 2009, 47:827-831.
9. Lauterbur PC, Dias MH, Rudin AM. In: Dutton PL, Leigh JS, Scarpa A, eds. Frontiers of Biological Energetics. New York: Academic Press; 1978, 752-759.
10. Mendonca-Dias MH, Gaggelli E, Lauterbur PC. Paramagnetic contrast agents in nuclear magnetic resonance medical imaging. Sem Nucl Med 1983, 13:364-76.
11. Wendland MF. Applications of manganese-enhanced magnetic resonance imaging (MEMRI) to imaging of the heart. NMR Biomed 2004, 17:581-594.
12. Thuen M, Berry M, Pedersen TB, Goa PE, Summerfield M, Haraldseth O, Sandvig A, Brekken C. Manganese-enhanced MRI of the rat visual pathway: acute neural toxicity, contrast enhancement, axon resolution, axonal transport, and clearance of Mn(2+). J Magn Reson Imaging 2008, 28:855-865.
13. Churin AA, Karpova GV, Fomina TI, Vetoshkina TV, Dubskaia TIu, Voronova OL, Filimonov VD, Belianin ML, Usov VIu. Preclinical toxicological evaluation of Pentamang and Mangascan. Eksp Klin Farmakol 2008, 71:49-52.
14. Santamaria AB. Manganese exposure, essentiality & toxicity. Indian J Med Res 2008, 128:484-500.
15. Bertin A, Michou-Gallani A-I, Gallani JL, Felder-Flesch D. In vitro neurotoxicity of magnetic resonance imaging (MRI) contrast agents: Influence of the molecular structure and paramagnetic ion. Toxicol in Vitro 2010, 24:1386-1394.
16. Unger E, Fritz T, Shen DK, Wu G. Manganese-based liposomes: comparative approach. Invest Radiol 1993, 28:933-938.
17. Aime S, Anelli PL, BOtta M, Brocchetta M, Canton S, Fedeli F, Gianolio E, Terreno E. Relaxometric evaluation of novel manganese (II) complexes for application as contrast agents in magnetic resonance imaging. J Biol Inorg Chem 2002, 7:58-67.
18. Troughton JS, Greenfield MT, Greenwood JM, Dumas S, Wiethoff AJ, Wang J, Spiller M, McMury TJ, Caravan P. Synthesis and evaluation of a high relaxivity manganese(II)-based mri contrast agent. Inorg Chem 2004, 43:6313-6323.
19. Schwendener RA, Wüthrich R, Duewell S, Wehrli E, von Schulthess GK. A pharmacokinetic and MRI study of unilamellar gadolinium-, manganese-, and iron-DTPA-stearate liposomes as organ-specific contrast agents. Invest Radiol 1990, 25:922-932.
20. Rongved P, Klaveness J. Water-soluble polysaccharides as carriers of paramagnetic contrast agents for magnetic resonance imaging: synthesis and relaxation properties. Carbohydr Res 1991, 214:315-323.
21. Buchler JW. Synthesis and properties of metalloporphyrins. In: Dolphin D, ed. The Porphyrins, vol I A. New York: Academic Press; 1979, 389-483.
22. Place DA, Faustino PJ, Berghmans KK, van Zijl PCM, Chesnick AS, Cohen JS. Magn Reson Imaging 1992, 10:919-928.
23. Fiel RJ, Musser DA, Mark EH, Mazurchuk R, Alletto J. J Magn Reson Imaging 1990, 8:255-259.
24. Schmiedl UP, Nelson JA, Robinson DH, Michalson A, Starr F, Frenzel T, Ebert W, Schuhmann-Giampieri G. Invest Radiol 1993, 28:925-932.
25. Fawwaz RA, Winchell HS, Frye F, Hemphill W, Lawrence JH. Localization of 58Co and 65Zn-hematoporphyrin complexes in canine lymph nodes. J Nucl Med 1969, 10:581-585.
26. Fawwaz RA, Hemphill W, Winchell HS. Potential use of Pd-porphyrin complexes for selective lymphatic ablation. J Nucl Med 1971, 12:231-236.
27. Fujimori H, Matsumura A, Yamamoto T, Shibata Y, Yoshizawa T, Nakagawa K, Yoshii Y, Nose T, Sakata I, Nakajima S. Tumor specific contrast enhancement study of Mn-metalloporphyrin (ATN-10)-comparison of rat brain tumor model, cytotoxic and vasogenic edema models. Acta Neurochir 1997, 70:167-169.
28. Takehara Y, Sakahara H, Masunaga H, Isogai S, Kodaira N, Sugiyama M, Takeda H, Saga T, Nakajima S, Sakata I. Assessment of a potential tumor-seeking manganese metalloporphyrin contrast agent in a mouse model. Magn Reson Med 2002, 47:549-553.
29. Shapiro EM, Koretsky AP. Convertible manganese contrast for molecular and cellular MRI. Magn Reson Med 2008, 60:265-269.
30. Leung KC, Wang YX, Wang H, Xuan S, Chak CP, Cheng CH. Biological and magnetic contrast evaluation of shape-selective Mn-Fe nanowires. IEEE Trans Nanobiosci 2009, 2:192-198.
31. Lu J, Ma S, Sun J, Xia C, Liu C, Wang Z, Zhao X, Gao F, Gong Q, Song B, Shuai X, Ai H, Gu Z. Manganese ferrite nanoparticle micellar nanocomposites as MRI contrast agent for liver imaging. Biomaterials 2009, 30:2919-2928.
32. Yang J, Lee CH, Ko HJ, Suh JS, Yoon HG, Lee K, Huh YM, Haam S. Multifunctional magneto-polymeric nanohybrids for targeted detection and synergistic therapeutic effects on breast cancer. Angew Chem Int Ed Engl 2007, 46:8836-8839.
33. Mertzman JE, Kar S, Lofland S, Fleming T, Keuren EV, Tong YY, Stoll SL. Surface attached manganese-oxo clusters as potential contrast agents. Chem Commun 2009, 45:788-790.
34. Li Z, Li W, Li X, Pei F, Wang X, Lei H. Mn(II)-monosubstituted polyoxometalates as candidates for contrast agents in magnetic resonance imaging. J Inorg Biochem 2007, 101:1036-1042.
35. Taylor KM, Rieter WJ, Lin W. Manganese-based nanoscale metal-organic frameworks for magnetic resonance imaging. J Am Chem Soc 2008, 130:14358-14359.
36. Na HB, Lee JH, An K, Park YI, Park M, Lee IS, Nam DH, Kim ST, Kim SH, Kim SW, Lim KH, Kim KS, Kim SO, Hyeon T. Development of a T1 contrast agent for magnetic resonance imaging using MnO nanoparticles. Angew Chem Int Ed Engl 2007, 46:5397-5401.
37. Shin J, Anisur RM, Ko MK, Im GH, Lee JH, Lee IS. Hollow manganese oxide nanoparticles as multifunctional agents for magnetic resonance imaging and drug delivery. Angew Chem Int Ed Engl 2009, 48:321-324.
38. Pan D, Senpan A, Caruthers SD, Williams TA, Scott MJ, Gaffney PJ, Wickline SA, Lanza GM. Sensitive and efficient detection of thrombus with fibrin-specific manganese nanocolloids. Chem Commun (Camb) 2009:3234-3236.
39. Pan D, Caruthers SD, Hu G, Senpan A, Scott MJ, Gaffney PJ, Wickline SA, Lanza GM. Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets. J Am Chem Soc 2008, 130:9186-9187.
40. Steibel BA, Michou-Gallani AI, Gallani JL, Felder-Flesch D. Development of a dendritic manganese-enhanced magnetic resonance imaging (MEMRI) contrast agent: synthesis, toxicity (in vitro) and relaxivity (in vitro, in vivo) studies. Bioconjug Chem 2009 20:760-767.
41. Lauterbur PC, Mendonça-Dias HM, Rudin AM. Augmentation of tissue water proton spin-lattice relaxation by in vivo addition of paramagnetic ions. In: Dutton PL, Leigh JS, Scarpa A, eds. Frontiers of Biological Energetics, vol 1. New York: Academic Press; 1978, 752-759.
42. Chen C-W, Cohen JS, Myers CE, Sohn M. Paramagnetic metalloporphyrins as potential contrast agents in NMR imaging. FEBS Lett 1984, 168:70-74.
43. Kreft BP, Baba Y, Tanimoto A, Finn JP, Stark DD. Orally administered manganese chloride: enhanced detection of hepatic tumors in rats. Radiology 1993, 186:543-548.
44. Greenberg DM, Copp DH, Cuthbertson EM. Studies in mineral metabolism with the aid of artificial radioactive isotopes. VII. The distribution and excretion, particularly by way of the bile, of iron, cobalt, and manganese. J Biol Chem 1943, 147:749-756.
45. Kojima S, Hirai M, Kiyozumi M, Sasawa Y, Nakagawa M, Shin-o T. Studies on poisonous metals. X. Metabolic fate of manganese after oral administration of excessive manganese chloride in rats. Chem Pharm Bull 1983, 31:2459-2465.
46. Sandström B, Davidsson L, Cederblad Å, Eriksson R, Lönnerdal B. Manganese absorption and metabolism in man. Acta Pharmacol Toxicol 1986, 59:60-62.
47. Koretsky AP, Silva AC. Manganese-enhanced magnetic resonance imaging (MEMRI). NMR Biomed 2004, 17:527-531.
48. Lee JH, Koretsky AP. Manganese enhanced magnetic resonance imaging. Curr Pharm Biotechnol 2004, 5:529-537.
49. Silva AC, Bock NA. Manganese-enhanced MRI: an exceptional tool in translational neuroimaging. Schizophr Bull 2008, 34:595-604.
50. Strijkers GJ, Mulder WJ, van Tilborg GA, Nicolay K. MRI contrast agents: current status and future perspectives. Anticancer Agents Med Chem 2007, 7:291-305.
51. Pautler RG. Biological applications of manganese-enhanced magnetic resonance imaging. Methods Mol Med 2006, 124:365-386.
52. Elizondo G, Fretz CJ, Stark DD, Rocklage SM, Quay SC, Worah D, Tsang YM, Chen MC, Ferrucci JT. Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging. Radiology 1991, 178(1):73-78.
53. Rocklage SM, Cacheris WP, Quay SC, Hahn FE, Raymond KN. Manganese(II) N, N'-Dipyridoxylethylenediamine-N, N'-diacetate 5, 5'-Bis(phosphate). Synthesis and Characterization of a Paramagnetic Chelate for Magnetic Resonance Imaging Enhancement. Inorg Chem 1989, 28:477-485.
54. Takehara Y, Sakahara H, Masunaga H, Isogai S, Kodaira N, Takeda H, Saga T, Nakajima S, Sakata I. Tumour enhancement with newly developed Mn-metalloporphyrin (HOP-9P) in magnetic resonance imaging of mice. Br J Cancer 2001, 84:1681-1685.
55. Atanasijevic T, Zhang X, Lippard SJ, Jasanoff A. MRI sensing based on the displacement of paramagnetic ions from chelated complexes Inorg Chem 2010, 49:2589-2591.
56. Lis T. Preparation, structure, and magnetic properties of a dodecanuclear mixed-valence manganese carboxylate. Acta Crystallogr, Sect B: Struct Crystallogr Cryst Chem 1980, 36:2042.
57. Caneschi A, Gatteschi D, Sessoli R, Barra A-L, Brunel L-C, Guillot M. Alternating current susceptibility, high field magnetization, and millimeter band EPR evidence for a ground S = 10 state in [Mn12O12(Ch3COO)16 (H2O)4].2CH3COOH.4H2O. J Am Chem Soc 1991, 113:5873.
58. Sessoli R, Gatteschi D, Caneschi A, Novak M. Magnetic bistability in a metal-ion cluster. Nature 1993, 365:141.
59. Christou G, Gatteschi D, Hendrickson D, Sessoli R. Single-molecule magnets. MRS Bull 2000, 25:66.